Becampanel (INN; development code AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC<sub>50</sub> = 11 nM). It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.